CAR T-cell Therapy CTX110 Shows Early Promise for Relapsed/Refractory CD19+ B-cell Malignancies

The allogeneic CD19-targeted CAR T-cell therapy CTX110 was found to elicit encouraging responses with favorable tolerability in patients with relapsed or refractory B-cell malignancies, according to data from the phase 1 CARBON trial.

The allogeneic CD19-targeted CAR T-cell therapy CTX110 was found to elicit encouraging responses with favorable tolerability in patients with relapsed or refractory B-cell malignancies, according to data from the phase 1 CARBON trial (NCT04035434).1

Among 23 patients who received the product at dose level 2, which was 100 x 106, or higher, CTX110 elicited an overall response rate (ORR) of 61% (n = 14), with a complete response (CR) rate of 39% (n = 9). Among all enrolled patients (n = 24) at dose level 2 or higher, the ORR was 58% (n = 14) and the CR rate was 38% (n = 9).

Notably, responses were observed in a variety of patients, including those with refractory disease, bulky disease, or those who experienced disease progression following autologous stem cell transplant.

“We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas [LBCLs] an immediately available ‘off-the-shelf’ therapy with efficacy similar to autologous CAR T and a differentiated safety profile,” Samarth Kulkarni, PhD, chief executive officer of CRISPR Therapeutics, stated in a press release. “Furthermore, we have the potential to improve upon already observed efficacy with a consolidation dosing strategy. Based on these encouraging results, we are planning to expand CARBON into a potentially registrational trial in the first quarter of 2022.”